Pancreatic Cancer Research

ResearcherFriedrich-Alexander-Universität Erlangen-NürnbergActive in the last 2 years

Maximilian Brunner

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9615-321X; OpenAlex author ID A5022613748. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 4 papers · 2023: 3 papers · 2024: 6 papers · 2025: 3 papers · 2026: 4 papers

Papers 23

  1. Enhancing multidisciplinary tumor board decision-making in pancreatic cancer using cinematic rendering. Co-author DOI 10.1016/j.pan.2025.12.025↗
  2. Prognostic impact of CRM-status on survival in patients with resected pancreatic adenocarcinoma - a dual-center cohort analysis. Co-author DOI 10.1016/j.suronc.2026.102422↗
  3. Immune Cell-Specific and Isoform-Selective Regulation of CD44 in Pancreatic Ductal Adenocarcinoma Links Lymph Node Variant Loss and Exosomal CD44 to Clinical O… Co-author DOI 10.3390/cells15050411↗
  4. Post-Surgical Remodeling of Circulating Monocytes Identifies CD86 Expression on Non-Classical Monocytes as a Prognostic Indicator in Pancreatic Ductal Adenocar… Co-author DOI 10.3390/ijms27115012↗
  5. Impact of Structured Postoperative Surveillance on Survival in Patients with Resected Pancreatic Adenocarcinoma. Last author DOI 10.3390/cancers17091424↗
  6. The Prognostic Role of Para-Aortic Lymph Node Metastasis in Patients with Resected Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17213418↗
  7. Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/ijms26072875↗
  8. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  9. Prognostic role of nutrition parameters on short- and long-term outcome in patients with primary resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.clnesp.2024.06.002↗
  10. Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients. Co-author DOI 10.1016/j.pan.2024.07.017↗
  11. CD71 expressing circulating neutrophils serve as a novel prognostic biomarker for metastatic spread and reduced outcome in pancreatic ductal adenocarcinoma pat… Co-author DOI 10.1038/s41598-024-70916-3↗
  12. Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival. Co-author DOI 10.3389/fimmu.2024.1253072↗
  13. Neutrophil-to-Lymphocyte Ratio and Prognostic Nutritional Index Are Predictors for Overall Survival after Primary Pancreatic Resection of Pancreatic Ductal Ade… Last author DOI 10.3390/cancers16162911↗
  14. Screening for pancreatic cancer in individuals with genetic susceptibility First author DOI 10.21037/hbsn-23-176↗
  15. Impact of Aspirin Intake on Postoperative Survival after Primary Pancreatic Resection of Pancreatic Ductal Adenocarcinoma-A Single-Center Evaluation. Last author DOI 10.3390/biomedicines11051466↗
  16. Circulating Monocytes Serve as Novel Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15020363↗
  17. [Pancreatic cystic space-occupying lesions-Diagnostics, treatment and follow-up care : Current recommendations taking the current German S3 guidelines on pancr… Co-author DOI 10.1007/s00104-022-01616-9↗
  18. [Better Therapy for Pancreatic Cancer through More Radical Surgery?] Co-author DOI 10.1055/a-1766-7643↗
  19. Impact of Patient Age on Postoperative Short-Term and Long-Term Outcome after Pancreatic Resection of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers14163929↗
  20. Time to Surgery Does Not Affect Overall or Disease-Free Survival of Patients with Primary Resectable PDAC. Last author DOI 10.3390/jcm11154433↗
  21. [Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. Co-author DOI 10.1055/a-1161-9501↗
  22. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ducta… Co-author DOI 10.3390/ijms21051779↗
  23. Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. Co-author DOI 10.3390/ijms20184543↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert Grützmann · 22 shared papers, 2019–2026 · strength 4.71
  2. Christian Krautz · 18 shared papers, 2019–2026 · strength 3.63
  3. Georg F. Weber · 17 shared papers, 2019–2026 · strength 3.35
  4. Anke Mittelstädt · 10 shared papers, 2022–2026 · strength 2.08
  5. Anne Jacobsen · 8 shared papers, 2020–2026 · strength 1.57
  6. Paul David · 6 shared papers, 2023–2026 · strength 1.10
  7. Frederik J. Hansen · 5 shared papers, 2023–2026 · strength 0.87
  8. Isabelle Kuchenreuther · 4 shared papers, 2024–2026 · strength 0.80
  9. Danilo Hackner · 4 shared papers, 2022–2024 · strength 0.76
  10. Lisa-Sophie Arnold · 3 shared papers, 2024–2026 · strength 0.58
  11. Alara Karabiber · 3 shared papers, 2024–2026 · strength 0.57
  12. Timur Buniatov · 2 shared papers, 2024–2026 · strength 0.43
  13. Georg J. Wiltberger · 1 shared paper, 2026 · strength 0.36
  14. Sophie Bareiß · 1 shared paper, 2024 · strength 0.26
  15. Tobias Keck · 2 shared papers, 2020–2024 · strength 0.24
  16. Waldemar H. Uhl · 2 shared papers, 2020–2024 · strength 0.24
  17. Jens Werner · 2 shared papers, 2020–2024 · strength 0.24
  18. Lena Häberle · 1 shared paper, 2022 · strength 0.22
  19. Iréne Esposito · 1 shared paper, 2022 · strength 0.22
  20. Yong Jian Zhou · 1 shared paper, 2026 · strength 0.22
  21. Sabine Semrau · 1 shared paper, 2024 · strength 0.15
  22. Yurdagül Zopf · 1 shared paper, 2024 · strength 0.15
  23. Axel Denz · 1 shared paper, 2024 · strength 0.15
  24. Marc Eric Martignoni · 1 shared paper, 2024 · strength 0.14
  25. Werner Hartwig · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.